AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

BDRX · NASDAQ · Biotechnology

Biodexa Pharmaceuticals (ADR) (BDRX)

Advancing licensed therapies for familial adenomatous polyposis, treatment-resistant GIST, and type 1 diabetes.

$0.7715

Pre-market−0.01 (−1.71%)

At close$0.7849(+0.53%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

	Insiders1 holder · as of Mar 18, 2026	0.00%	0 ADS
	Otherremainder	100.00%	1.13M ADS

1.13M ADS (1 ADS = 4 ordinary shares) as of Sep 3, 2026 · holders as of their latest filing

Two share counts disagree (1.13M in the company's Sep 3, 2026 report, 746.1K elsewhere); stakes use the report.

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
Simon TurtonInsiderdirector	0.00%	0	Form 4filed Mar 18, 2026 ↗
Armistice Capital, LLCStrategic	—9.99% of class, as filed	—	13Gfiled May 15, 2026 ↗
Capital Master Fund Ltd.Strategic	—9.83% of class, as filed	—	13Gfiled Jul 23, 2024 ↗
Sabby Management, LLCStrategic	—9.90% of class, as filed	—	13Gfiled Jan 20, 2026 ↗

13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F

No 13F holders on record.

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Form	Filed
Armistice Capital, LLC	9.99%	13G	May 15, 2026 ↗
Sabby Management, LLC	9.90%	13G	Jan 20, 2026 ↗
Cavalry Fund I LP	5.70%	13G	May 28, 2025 ↗

Biodexa Pharmaceuticals (ADR) (BDRX)

Breakdown13F · 13D/G · Form 4

Top shareholders13F · 13D/G · Form 4

Institutions13F

Ownership statements13D/G · 5% or more, as filed

Insider tradesForm 4

Latest trades

CongressHouse and Senate disclosures